PTP4A3 and cancer: Importantly, studies have consistently found minimal or no PRL3 protein expression in patient-matched normal tissues, which affirms PRL3 as a highly tumor-specific target and suggest targeting PRL3 is a promising strategy for effective treatment of many cancer types with potentially few side effects.